ARCA Biopharma Completes Merger with Oruka Therapeutics
ARCA biopharma, Inc. (NASDAQ: ABIO) has successfully completed its merger with Oruka Therapeutics, Inc., marking a pivotal moment for the company. This merger was finalized after obtaining stockholder approval for all related proposals.
Results from the Stockholder Meeting
The recent stockholder meeting yielded a positive outcome, with investors expressing strong support for the merger with Oruka. This agreement demonstrates the confidence that stockholders have in the strategic direction of the newly combined entities.
Merger Details
With the merger now complete, Oruka has become a wholly-owned subsidiary of ARCA. In this transition, each share of Oruka common stock was converted into 6.8569 shares of ARCA common stock. This conversion follows standard procedures during mergers to ensure fair distribution of shares among all stakeholders.
Special Cash Dividend Announcement
In conjunction with the merger's completion, ARCA declared a special cash dividend of $1.613 per share for shareholders who were on record as of a recent date. This initiative aims to reward stakeholders during this significant transition and reorganization phase.
Reverse Stock Split Implementation
The newly formed company plans to execute a reverse stock split of its common stock at a ratio of 1-for-12. This adjustment will take place shortly after the merger's finalization, with the reverse split set for a specific date. Under this arrangement, every 12 shares of the combined company’s stock will be consolidated into one share.
Effects on Stockholders
Stockholders will receive cash for any fractional shares resulting from the reverse stock split. Those who hold shares through banks, brokers, or nominees will see their positions automatically adjusted, requiring no additional action on their part, thereby accommodating stakeholders during this transition.
Future Operations and Trading
After the merger, the combined entity will operate under the name Oruka Therapeutics, Inc. It is expected that shares of the new company will begin trading on The Nasdaq Global Market under the ticker symbol “ORKA.” This listing is a crucial step in establishing the company’s new identity within the market.
About Oruka Therapeutics
Oruka Therapeutics is dedicated to developing innovative biologics aimed at transforming treatment methods for chronic skin diseases. Their mission is to empower patients dealing with conditions like plaque psoriasis, significantly enhancing their quality of life. Oruka aims to achieve optimal outcomes with less frequent dosing schedules, potentially redefining the standard of care in dermatology.
Conclusion
The merger positions ARCA biopharma for growth within the biopharmaceutical sector, particularly in addressing dermatological conditions. The strategic alliance with Oruka Therapeutics reflects a forward-thinking approach to innovative treatments that could greatly benefit patients.
Frequently Asked Questions
What was the outcome of the merger between ARCA and Oruka?
The merger was successfully completed, resulting in Oruka becoming a wholly-owned subsidiary of ARCA biopharma.
What changes will shareholders see following the reverse stock split?
Shareholders will experience a consolidation of their shares at a 1-for-12 ratio and may receive cash for any fractional shares.
When will the new company begin trading under its new ticker?
The combined company will commence trading under the ticker symbol “ORKA” after the merger and reverse stock split are finalized.
What is the role of Oruka Therapeutics in this merger?
Oruka Therapeutics specializes in developing innovative treatments for chronic skin diseases, thereby enhancing the potential of ARCA’s pipeline.
Who can shareholders contact for more information about the merger?
Shareholders can reach out to Alan Lada for further inquiries regarding the recent merger and its implications.
